Your Cart is Empty
Tranexamic acid and hydroquinone are different compounds, and topical TXA should not automatically be described as equivalent to hydroquinone. Some melasma trials report similar short-term outcomes for specific preparations. That does not establish interchangeable effectiveness, safety or regulatory status for every product.
For the TXA foundation, read the ingredient guide. This comparison focuses on evidence and U.S. treatment context rather than providing an individualized regimen.
Hydroquinone is a pigment-reducing drug ingredient with a long history in melasma care. TXA’s proposed pigmentation pathway involves plasmin-related skin-cell signaling. They are not alternate names for the same substance.
Our TXA mechanism guide explains the signaling research. Mechanistic differences are useful context, but cannot determine which treatment is appropriate for an individual diagnosis.
A 2019 randomized, single-blind study compared 5% TXA solution with 3% hydroquinone cream over 12 weeks, analyzing 100 participants with melasma. Pigmentation scores improved similarly, without a significant between-group difference. Reported irritation was less frequent with TXA.
The preparations used different carriers, and follow-up was short. The findings support interest in that TXA preparation; they do not establish that any retail TXA serum matches any hydroquinone treatment. A nonsignificant difference is also not the same as a trial designed to prove equivalence.
A comparison with an active treatment answers a different question from a comparison with a vehicle. The topical TXA melasma review includes mixed findings and explains why before-and-after improvement alone can be misleading.
Keep oral TXA results separate as well. Our route guide explains why a prescription-tablet study cannot substantiate a claim about a cosmetic serum.
The FDA explains that OTC hydroquinone skin-lightening products require an approved new drug application under the current U.S. framework; there are no FDA-approved OTC hydroquinone skin-lightening products. This does not mean that every medical use of hydroquinone is prohibited.
An FDA-approved prescription combination exists for a specific melasma indication. Other prescription or compounded preparations should not automatically be called FDA-approved. The FDA has also reported adverse effects from hydroquinone skin-lightening products, including rashes, swelling and ochronosis.
These distinctions are reasons to discuss hydroquinone with a qualified clinician, rather than treating an online product listing as proof of approval or suitability.
The FDA generally does not preapprove cosmetics, apart from certain color-additive requirements. A TXA cosmetic being available for sale therefore does not establish FDA confirmation of its pigment benefits.
Likewise, a brand’s reference to a study of another TXA preparation is not automatically evidence for its own formula. Use the selection guide to distinguish ingredient research from finished-product evidence.
For suspected melasma, the general melasma guide provides the broader care context. Do not stop or replace a prescribed treatment solely on the basis of a cosmetic ingredient comparison.
Whichever approach is appropriate, sun protection for pigmentation remains a separate part of care. TXA and hydroquinone are not substitutes for it, and neither ingredient name provides a universal solution for every dark spot.
